7 March 2019 - - US-based biopharmaceutical company Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, have enrolled the first patient in the expansion stage of a Phase 1/2 clinical trial of tinostamustine, an investigational treatment, in patients with relapsed refractory hematologic malignancies in the US and Europe, the company said.

Following a dose escalation trial to establish tolerability, this expansion phase seeks to investigate the overall response rate, duration of response and safety of five cohorts of patients with R/R cancers, including: multiple myeloma, Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma and T-cell prolymphocytic leukemia. Each study arm will run separately, with results to be submitted for upcoming medical meetings.

In addition to tinostamustine, Imbrium's clinical stage oncology portfolio includes etoposide toniribate, a novel prodrug with a target cell-activated topoisomerase inhibitor. Imbrium is currently collaborating in research for four drug candidates across 14 different cancer types.

Research on these compounds is being advanced on behalf of Imbrium by Mundipharma EDO.

Imbrium Therapeutics, in collaboration with Mundipharma EDO GmbH, expects to continue enrollment in the Phase 1/2 trial. To learn more about the trial, visit clinicaltrials.gov.

Hematologic malignancies are forms of cancer in the cells of blood-forming tissue or in the cells of the immune system.

Examples of hematologic cancer are acute and chronic leukemias, lymphomas, multiple myeloma and myelodysplastic syndromes. In most blood cancers, the normal blood cell development process is interrupted by uncontrolled growth of an abnormal type of blood cell.

These cancerous cells prevent the blood from performing many of its functions.

Tinostamustine is an alkylating deacetylase inhibiting molecule (AK-DACi) in development for a range of rare or difficult-to-treat blood cancers and solid tumors.

It is a multi-action therapy and is currently in Phase 1 clinical trials. Pre-clinical studies with tinostamustine as monotherapy have shown response, in myeloid and lymphoid malignancies and solid tumors.

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.

The company is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain.

Mundipharma EDO is part of the Mundipharma global network of privately-owned independent associated companies, which operate in over 120 countries worldwide.

It develops treatments for patients around the world with rare or R/R cancer, investigating smart approaches to new cancer treatments from concept through to clinical development and regulatory approval.

Mundipharma is a global network of privately-owned independent associated companies.